EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Quoin Pharmaceuticals's enterprise value is $-11.60 Mil.
Quoin Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.59 Mil. Therefore, Quoin Pharmaceuticals's EV-to-EBITDA for today is 1.35.
The historical rank and industry rank for Quoin Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
QNRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.56 Med: 0 Max: 1.91
Current: 1.35
During the past 5 years, the highest EV-to-EBITDA of Quoin Pharmaceuticals was 1.91. The lowest was -10.56. And the median was 0.00.
QNRX's EV-to-EBITDA is ranked better than 65.04% of 452
companies
in the Biotechnology industry
Industry Median: 9.47
vs QNRX: 1.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Quoin Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Quoin Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Quoin Pharmaceuticals's EV-to-EBITDA
For the Biotechnology subindustry, Quoin Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quoin Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Quoin Pharmaceuticals's EV-to-EBITDA falls into.
Quoin Pharmaceuticals's current Enterprise Value is $-11.60 Mil.
Quoin Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Quoin Pharmaceuticals's PE Ratio for today is calculated as:
Quoin Pharmaceuticals's share price for today is $0.73.
Quoin Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Quoin Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Quoin Pharmaceuticals (Quoin Pharmaceuticals) Business Description
Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
QNRX has been successfully added to your 